Stem cells are the body's ultimate shape-shifters, sustaining tissues by balancing two competing demands: maintaining their ...
A single week of intensive meditation and mind-body practices led to measurable changes across the brain and body. Researchers observed improved brain efficiency, boosted immune signaling, and ...
More than 10 loss-making biotechnology companies have filed for Hong Kong stock exchange listings this year, bringing cutting-edge drugs and artificial intelligence-powered drug discovery platforms to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Orders for CyPath® Lung by physicians and clinics rose 67% YoY due to peer-to-peer marketing, positive real-world experiences and growing test awareness SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity ...
Scientists have built a massive cellular atlas showing how aging reshapes the body across 21 organs. Studying nearly 7 million cells, they found that aging starts earlier than expected and unfolds in ...
Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through a collaboration that could ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Company plans to initiate a Phase 1 clinical study by 1H2026 and share data in 2027 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) ...
Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results